Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

This database provides information about selected rodent models of neurodegenerative disease, including Alzheimer’s, Parkinson’s, and ALS. By summarizing, visualizing, and continuously updating ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

To mark the 20th anniversary of Alzforum's launch in 1996, we have compiled a timeline reflecting the evolution of Alzheimer’s disease research, starting from Alois Alzheimer's public presentation of ...

Series - Clinical Trials on Alzheimer's Disease 2018: Part 1 of 10: Bump in the Road or Disaster? BACE Inhibitors Worsen Cognition Part 2 of 10: Second Look at BAN2401 Data Still Positive, Despite ...

A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

However, diagnostic tests do not need FDA approval to be marketed to the public. They can clear a lower bar by becoming CLIA-approved, meaning the assay has good test-retest reproducibility. Quest's ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

Series - AAT-AD/PD™ 2020 Conference: Advances in Alzheimer's and Parkinson's Therapies: Part 1 of 12: New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better Part 2 of 12: 217—The Best Phospho-Tau ...